Cost-effectiveness in the use of antibiotics

Current Clinical Topics in Infectious Diseases

Volumn , Issue 20, 2000, Pages 24-42

  Mcnabb, Jocarol ^a   Quintiliani, Richard ^a   Nicolau, David P ^a   Grant, E D ^a   Nightingale, Charles H ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

AREA UNDER THE CURVE; COST BENEFIT ANALYSIS; COST CONTROL; CROSS INFECTION; ECONOMICS; HEALTH CARE QUALITY; HOSPITAL MANAGEMENT; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MICROBIOLOGICAL EXAMINATION; ORAL DRUG ADMINISTRATION; REVIEW;

ADMINISTRATION, ORAL; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; COST SAVINGS; COST-BENEFIT ANALYSIS; CROSS INFECTION; HOSPITAL ADMINISTRATION; HUMANS; INFUSIONS, INTRAVENOUS; MICROBIAL SENSITIVITY TESTS; QUALITY OF HEALTH CARE;

EID: 0034566244     PISSN: 01953842     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (58)

1. Leggett JE, Ebert S, Fantin B, Craig WA. Comparative dose-effect relations at several dosing intervals for beta-lactam, aminoglycoside and quinolone antibiotics against gram-negative bacilli in murine thigh-infection and pneumonitis models. Scand J Infect Dis 1991; 74:179-184.
2. Leggett JE, Fantin B, Ebert S, et al. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. J Infect Dis 1989; 159:281-292.
3. Roosendaal R, Bakker-Woudenberg IAJM, van den Berghe JC, Michel MF. Therapeutic efficacy of continuous versus intermittent administration of ceftazidime in an experimental Klebsiella pneumoniae pneumonia in rats. J Infect Dis 1985;156:373-378.
4. Onyeji CO, Nicolau DP, Nightingale CH, Quintiliani R. Optimal times above MIC's of ceftibuten and cefaclor in experimental intra-abdominal infections. Antimicrob Agents Chemother 1994;38:1112-1117.
5. Bodey GP, Ketchel SJ, Rodriguez V. A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients. Am J Med 1979;67: 608-616.
6. Bakker-Woudenberg IAJM, van den Bergh JC, Fontijne P, Michel MF. Efficacy of continuous versus intermittent administration of penicillin G in Streptococcus pneumoniae pneumonia in normal and immunodeficient rats. Eur J Clin Microbiol 1984;3:131-B5.
7. Gilbert DN. Once-daily aminoglycoside therapy. Antimicrob Agents Chemother 1991; 35:399-405.
8. Powell SH, Thompson WL, Luthe MA, et al. Once-daily vs. continuous aminoglycoside dosing: efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin. J Infect Dis 1983;147:918-932.
9. Wood CA, Norton DR, Kohlhepp SJ, et al. The influence of tobramycin dosage regimens on nephrotoxicity, ototoxicity and antibacterial efficacy in a rat model of subcutaneous abscess. J Infect Dis 1988;158:13-22.
10. Nicolau DP, Freeman CD, Belliveau PP, et al. Experience with a once-daily amino-glycoside program administered to 2184 adult patients. Antimicrob Agents Chemother 1995; 39:3:650-655.
11. Rozdzinski E, Kern WV, Reichle A, et al. Once-daily vs. thrice-daily dosing of netilmicin in combination with β-lactam antibiotics as empirical therapy for febrile neutropenic patients. J Antimicrob Chemother 1993;31: 585-598.
12. Prins JM, Buller HR, Kuijpcr EJ, et al. Once vs. thrice daily gentamicin in patients with serious infections. Lancet 1993;341:335-339.
13. Hatala R, Dinh T, Cook DJ. Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis. Ann Intern Med 1996; 124:717-725.
14. Vigano A, Principi N, Brivio L, et al. Comparison of 5 milligrams of netilmicin per kilogram of body weight once daily versus 2 milligrams per kilogram thrice daily for treatment of gram-negative pyelonephritis in children. Antimicrob Agents Chemother 1992;36: 1499-1503.
15. Langhendries JP, Battisti O, Bertrand JM, et al. Once-a-day administration of amikacin in neonates: assessment of nephrotoxicity and ototoxicity. Dev Pharmacol Ther 1993;20:220-230.
16. Marik PE, Lipman J, Kobilski A, Scribante J. A prospective randomized study comparing once- vs. twice-daily amikacin dosing in critically ill adult and pediatric patients. J Antimicrob Chemother 1991;28:753-764.
17. Viscoli C, Dudley M, Ferrea G, et al. Serum concentrations and safety of single daily dosing of amikacin in children undergoing bone marrow transplantation. J Antimicrob Chemother 1991;27(suppl C):113-120.
18. Nicolau DP, Wu AHB, Finocchiaro S, et al. Once-daily aminoglycoside dosing: impact on requests and costs for therapeutic drug monitoring. Ther Drug Monitor 1996;18:263-266.
19. Hitt CM, Klepser ME, Nightingale CH, et al. Pharmacoeconomic impact of once-daily aminoglycoside administration. Pharmacotherapy 1997;17:810-814.
20. Belliveau PP, Nicolau DP, Nightingale CH, Quintiliani R. Once-daily gentamicin: experience in one hundred eighteen patients with postpartum endometritis. J Infect Dis Pharmacother 1995;1:11-18.
21. Mithani H, Brown G. The economic impact of once-daily versus conventional administration of gentamicin and tobramycin. Pharmacoeconomics 1996;10:494-503.
22. Thurcen PJ, Reiter PD, Gresorcs A, et al. Once- versus twice-daily gentamicin dosing in neonates ≥34 weeks' gestation: cost-effectiveness analyses. Pediatrics 1999;103:594-598.
23. Craig WA. Interrelationships between pharmacokinetic and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diag Microbiol Infect Dis 1995;22:89-96.
24. Vogelman B, Gundmundson S, Leggett J, et al. Correlation of antimicrobial pharmacokinetic parameters with efficacy in an animal model. J Infect Dis 1988;158:831-847.
25. Peterson LR, Gerding DN, Fasching CE. Effects of method of antibiotic administration on extravascular penetration: cross-over study of cefazolin given by intermittent injection or constant infusion. J Antimicob Chemother 7:71-79.
26. Plorde J, Garcia M, Petersdorf RG. Studies on the pathogenesis of meningitis. IV penicillin levels in the cerebrospinal fluid in experimental meningitis. J Lan Clin Med 1964;64: 960-969.
27. Ambrose PG, Quintiliani R, Nightingale CH, Nicolau DP. Continuous vs. intermittent infusion of cefuroxime for the treatment of community-acquired pneumonia. IDCP 1998; 7:463-470.
28. Nicolau DP, Lacy MK, McNabb J, et al. Pharmacokinetics of continuous and intermittent ceftazidime in intensive care unit patients with nosocomial pneumonia. IDCP 1999;8: 45-49.
29. Ambrose PG, Bui K, Richerson M, et al. Pharmacokinetic and economic evaluation of piperacillin/tazobactam administered either as a continuous or intermittent infusion with once-daily gentamicin. IDCP 1999;8:195-200.
30. Zosyn Package Insert. Lederle Piperacillin, Inc. 1997.
31. Performance Standards for Antimicrobial Susceptibility Testing; Eighth Informational Supplement. Approved Standard NCCLS Document M100-S8, Vol 18, No. 1, NCCLS, Wayne, PA, January 1998.
32. Hitt CM, Patel KB, Nicolau DP, et al. Influence of piperacillin-tazobactam on pharmacokinetics of gentamicin given once daily. Am J Health-Syst Pharm 1997;54:2704-2708.
33. Hitt CM, Nightingale CH, Quintiliani R, Nicolau DP. Cost comparison of single daily doses of ceftriaxone versus continuous infusion of cefotaxime. Am J Health-Syst Pharm 1997; 54:1614-1618.
34. Zeisler JA, McCarthy JD, Richelieu WA, Nichol MB. Cefuroxime by continuous infusion: a new standard of care? Infect Med 1992;11:54-60.
35. Coultry R, Sanbourn M, Klutman NE, Strayer AH. Continuous infusion of ceftazidime with an elastomeric infusion device. Am J Health-Syst Pharm 1998;55:145-149.
36. Vinks MM, Brimicombe RW, Heijerman HG, Bakker W. Continuous infusion of ceftazidime in cystic fibrosis patients during home treatment: clinical outcome, microbiology and pharmacokinetics. J Antimicrob Chemother 1997;40:125-133.
37. Benko AS, Cappelletty DM, Kruse JA, Rybak MJ. Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections. Antimicrob Agents Chemother 1996; 40:691-695.
38. Bosso JA, Bonapace CR, Flume PA, White RL. A pilot study of the efficacy of constant-infusion ceftazidime in the treatment of endobronchial infections in adults with cystic fibrosis. Pharmacotherapy 1999;19:619-626.
39. James JK, Palmer SM, Levine DP, Rybak MJ. Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections. Antimicrob Agents Chemother 1996;40:696-700.
40. Wepser ME, Patel KB, Nicolau DP, et al. Comparison of bactericidal activities of intermittent and continuous infusion dosing of vancomycin against methicillin-resistant Staphylococcus aureus and Enterococcus faecalis. Pharmacotherapy 1998;18:1069-1074.
41. Owens CA, Ambrose PG, Quintiliani R, et al. Infusion phlebitis relative incidence associated with cefuroxime administered by intermittent infusion and continuous infusion. Clin Drug Invest 1998;15:525-529.
42. Quintiliani R, Cooper BW, Brieeland LL, Nightingale CH. Economic impact on streamlining antibiotic administration. Am J Med 1987;82:391-394.
43. Quintiliani R, Nightingale CH. Antimicrobials and therapeutic decision making: an historical perspective. Pharmacotherapy 1991; 11(suppl 1):6S-13S.
44. Klepser ME, Banevicius MA, Quintiliani R, Nightingale CH. Characterization of bactericidal activity of clindamycin against Bacteroides fragilis via kill curve methods. Antimicrob Agents Chemother 1996;40:1941-1944.
45. Klepser ME, Nicolau DP, Quintiliani R, Nightingale CH. Bactericidal activity of low-dose clindamycin administered at 8- and 12-hour intervals against Staphylococcus aureus, Streptococcus pneumoniae, and Bacteroides fragilis. Antimicrob Agents Chemother 1997; 41:630-635.
46. Earl P, Sisson PR, Ingliam HR. Twelve-hourly dosage schedule for oral and intravenous metronidazole. J Antimicrob Chemother 1989; 23:619-621.
47. Bunz D, Gupta S, Jewesson P. Metronidazole cost containment: a two-stage intervention. Hosp Formul 1990;25:1167-1177.
48. Ambrose PG, Richerson MA, Stanton ME, et al. Cost-effectiveness analysis of cefepime compared with ceftazidime in patients with hospital-acquired pneumonia. IDCP 1999 (in press).
49. Paladino JA. Cost-effectiveness comparison of cefepime and ceftazidime using decision analysis. Pharmacoeconomics 1994;5:505-512.
50. Maki DG. Infection due to infusion therapy. In: Bennett JV, Brachman PA, eds. Hospital infection. Boston: Little, Brown, 1986:561-580.
51. Read I, Bodey GP. Infectious complications of indwelling vascular catheters. Clin Infect Dis 1992;15:197-210.
52. Arnow PM, Quimosing EM, Beach M. Consequences of intravascular catheter sepsis. Clin Infect Dis 1993;16:778-784.
53. Frighetto L, Nickoloff D, Martinusen SM, et al. Intravenous-to-oral stepdown program: four years of experience in a large teaching hospital. Ann Pharmacother 1992;26:1447-2451.
54. Hendrickson JR, North DS. Pharmacoeconomic benefit of antibiotic step-down therapy: converting patients from intravenous ceftriaxone to oral cefpodoxime proxetil. Ann Pharmacother 1995;29:561-565.
55. Ehrenkranz NJ, Nerenberg DE, Shultz JM, Slater KC. Intervention to discontinue parenteral antimicrobial therapy in patients hospitalized with pulmonary infections: effect on shortening patient stay. Infect Control Hosp Epidemiol 1992;13:21-32.
56. Ramirez JA, Srinath L, Ahkee S, Huang A, Raff, MJ. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia. Arch Intern Med 1995;155:1273-1276.
57. Ramirez JA, Sunket A. Cost savings resulting from early switch to oral cefixime in hospitalized patients with CAP. Infect Med 1996;13: 616-620.
58. Partsch DJ, Paladino JA. Cost-effectiveness comparison of sequential ofloxacin versus standard switch therapy. Ann Pharmacother 1997;31:1137-1145.